

Datasheet: HCA214

Description:	HUMAN ANTI INFLIXIMAB
Specificity:	INFLIXIMAB
Other names:	Remicade
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD19376
Isotype:	HuCAL Fab monovalent
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

A monovalent human recombinant Fab (lambda light chain) selected from the HuCAL® phage display library, expressed in *E. coli*. The antibody is tagged with a DYKDDDDK tag and a HIS-tag (HHHHHH) at the C-terminus of the antibody heavy chain.

Preparation

Metal chelate affinity chromatography

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.01% Thiomersal

Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml

Immunogen

Infliximab

Specificity

Human Anti-Infliximab Antibody, clone AbD19376 is an anti-idiotypic antibody that specifically recognizes the infliximab monoclonal antibody and does not inhibit the binding of infliximab to its target, tumor necrosis factor alpha (TNF α). It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.

Clone AbD19376 recognizes both the free infliximab monoclonal antibody and infliximab when bound to TNF α (the drug/target complex); it is not paratope-specific and it is non-inhibitory. This

antibody can be used as a capture antibody in a pharmacokinetic (PK) bridging ELISA to detect total drug (free, partially bound and fully bound) with [HCA216P](#) as the detection antibody.

Infliximab (branded as Remicade) is a chimeric monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. It acts by blocking the binding of TNF α to its receptors. Infliximab also induces apoptosis of TNF α expressing T-lymphocytes.

[View a summary of all Anti-Infliximab Antibodies.](#)

Affinity	The monovalent intrinsic affinity of this antibody was measured as $K_D=0.7$ nM by real time, label-free molecular interaction analysis on immobilized infliximab.
ELISA	This product may be used in an indirect ELISA or as a capture antibody in an Infliximab bridging ELISA together HRP-conjugated HCA213 or HCA216 as the detection reagent. Protocol: PK bridging ELISA to measure total drug
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Remicade is a registered trademark of Janssen Biotech Inc. Inflectra is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS is a trademark of Merck Sharp & Dohme Corp. His-tag is a registered trademark of EMD Biosciences.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Secondary Antibodies

Mouse Anti Synthetic Peptide HISTIDINE TAG (MCA5995...) [HRP](#)

Rabbit Anti Synthetic Peptide DYKDDDDK TAG (AHP1074...) [HRP](#)

Rat Anti Synthetic Peptide DYKDDDDK TAG (MCA4764...) [HRP](#)

Recommended Useful Reagents

[HUMAN ANTI INFLIXIMAB \(HCA216\)](#)

[HUMAN ANTI INFLIXIMAB \(HCA215\)](#)
[HISPEC ASSAY DILUENT \(BUF049A\)](#)
[GOAT ANTI HISTIDINE TAG:Biotin \(AHP1656B\)](#)
[MOUSE ANTI HISTIDINE TAG:ALK.PHOS. \(MCA1396A\)](#)
[MOUSE ANTI HISTIDINE TAG:Biotin \(MCA1396B\)](#)
[RECOMBINANT HUMAN TNF ALPHA \(PHP051\)](#)
[MOUSE ANTI HUMAN IgG \(Fc\) CH2 DOMAIN:HRP \(MCA647P\)](#)
[HUMAN ANTI INFLIXIMAB \(HCA213\)](#)

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

'M371637:200612'

Printed on 11 Aug 2020

© 2020 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)